← Back to Clinical Trials
Recruiting NCT06888258

NCT06888258 Compare Analgesia Between MTP Block And ESPB in MRM

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06888258
Status Recruiting
Phase
Sponsor National Cancer Institute, Egypt
Condition Breast Cancer
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2024-10-01
Primary Completion 2025-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Ultrasound guided Erector Spinae Plane blockUltrasound guided Mid-point to Pleura block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2024-10-01 with a primary completion date of 2025-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is conducted to compare the analgesic efficacy between ultrasound guided Erector Spinae Plane block Vs midpoint transverse process to Pleura block in modified radical mastectomy surgeries

Eligibility Criteria

Inclusion Criteria: * ASA I-II. * Undergoing modified radical mastectomy surgery. * Body mass index (BMI) from 18.5 to 30 kg/m2 Exclusion Criteria: * Patient refusal. * Known allergy to local anesthetics. * Bleeding disorders; platelets count \<50,000 , prothrombin concentration \< 60% or any coagulopathy disorder. * Use of any anti-coagulants. * Inability to provide informed consent. * ASA III-IV. * Neurological disorders. * Patient with psychiatric disorders

Contact & Investigator

Central Contact

mahmoud Saad Mahmoud Mohamed Mohamed, Msc

✉ doc.mahmoudsaad@gmail.com

📞 +201094555375

Principal Investigator

Maie Kamal El-Din Helaly, MD

STUDY DIRECTOR

National cancer institute, Cairo University

Frequently Asked Questions

Who can join the NCT06888258 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06888258 currently recruiting?

Yes, NCT06888258 is actively recruiting participants. Contact the research team at doc.mahmoudsaad@gmail.com for enrollment information.

Where is the NCT06888258 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06888258 clinical trial?

NCT06888258 is sponsored by National Cancer Institute, Egypt. The principal investigator is Maie Kamal El-Din Helaly, MD at National cancer institute, Cairo University. The trial plans to enroll 90 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology